Form 4: Romness Paul A. reports acquisition/exercise transactions in OSTX

Rhea-AI Filing Summary

Romness Paul A. reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 1,000,000 shares. Following the reported transactions, holdings were 1,000,000 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Romness Paul A.

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock options (right to buy)	1,000,000	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock options (right to buy) — 1,000,000 shares (Direct); Common Stock — 2,473,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Romness Paul A.

(Last) (First) (Middle)

C/O OS THERAPIES INCORPORATED

115 PULLMAN CROSSING ROAD, SUITE 103

(Street)

GRASONVILLE MD 21638

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OS Therapies Inc [ OSTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								2,473,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	$1.34	01/22/2026		A		1,000,000		(1)	01/22/2036	Common Stock	1,000,000	$0	1,000,000	D

Explanation of Responses:

1. On January 22, 2026, the reporting person was granted options to purchase 1,000,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on such date.

	/s/ Paul A. Romness	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did OS Therapies (OSTX) disclose about Paul Romness in this Form 4?

OS Therapies reported that President and CEO Paul A. Romness received a grant of 1,000,000 stock options on January 22, 2026, and now directly beneficially owns 2,473,000 common shares plus these options.

How many OS Therapies (OSTX) stock options were granted to Paul Romness?

Paul A. Romness was granted 1,000,000 stock options to purchase OS Therapies common stock. The options were awarded under a stock option agreement and give him the right to buy 1,000,000 shares at a fixed exercise price if vesting conditions are met.

What is the exercise price and term of the new OS Therapies (OSTX) options?

The newly granted options have an exercise price of $1.34 per share and expire on January 22, 2036. This means Romness can choose to buy shares at $1.34 any time after vesting until that expiration date.

When do Paul Romness’s OS Therapies (OSTX) stock options vest?

The 1,000,000 OS Therapies stock options granted to Paul A. Romness vest in full on the one-year anniversary of the January 22, 2026 grant date, provided he is serving as an employee of the company on that vesting date.

How many OS Therapies (OSTX) shares does Paul Romness own after this Form 4?

Following the reported transaction, Paul A. Romness directly beneficially owns 2,473,000 shares of OS Therapies common stock. In addition, he holds 1,000,000 stock options that, once vested, allow him to purchase more shares at the fixed exercise price.

Is the OS Therapies (OSTX) Form 4 a stock purchase or an option grant?

The Form 4 reports an option grant, not an open-market stock purchase. Paul A. Romness received 1,000,000 stock options as a grant at a $1.34 exercise price, which he can exercise for shares after the options vest and before expiration.